[{"id":"9436a8ff-5aa6-4f94-a70c-ecf2cecaa874","acronym":"NCI-2022-02215","url":"https://clinicaltrials.gov/study/NCT05285813","created_at":"2023-08-14T10:11:07.915Z","updated_at":"2024-07-02T16:34:58.922Z","phase":"Phase 2","brief_title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","source_id_and_acronym":"NCT05285813 - NCI-2022-02215","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vibecotamab (XmAb14045)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/06/2022","start_date":" 05/06/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-04"}]